New Hope for People With Asthma & Eczema
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
New understanding of a receptor key to allergic responses and anaphylaxis in conditions like asthma could offer a new treatment target for sufferers of a variety of conditions.
This the promise of a study by researchers from China's Shenzhen and Wuhan universities, which have identified a mechanism that sustains the release of allergy-stimulating molecules from cells.
Allergic conditions like asthma (affecting around 28 million people in the US) and eczema (31.6 million) have been on the rise in recent decades.
The diseases are triggered by a type of white blood cell called mast cells, which release inflammatory molecules that promote allergic responses and create symptoms like itching, swelling and difficulty breathing.
An illustration of an activated mast cell releasing histamine.
An illustration of an activated mast cell releasing histamine.Allergic reactions begin when antibodies called 'lgE' produced by the immune system interact with 'FcεRI'—a receptor involved in allergies and parasite immunity—and antigens (a substance causing the immune system to react) on mast cells. This, the researchers explained, "set[s] the stage" for the release of allergic mediators.
While scientists have considered targeting FcεRI as a promising treatment approach, it has so far been challenging to implement in the clinic.
In the new study, however, the researchers focused on an enzyme called USP5, which controls the turnover of proteins and has been linked to inflammatory diseases like gum disease.
They discovered that mast cells are dependent on USP5 to release allergy signaling molecules called histamine (hence common allergy medications called antihistamines) and β-hexosaminidase in response to lgE and antigen.
The discovery, the researchers wrote, demonstrates "that USP5 may be an important target in the treatment of type I allergic diseases."
Type I allergic diseases include hay fever, food allergy, anaphylaxis, most types of asthma and urticaria.
"They are all IgE mediated reactions that involve mast cells as a shared target, but there are multiple pathways that contribute to their severity so it's not as simple as blocking one receptor, but it could be a useful addition to current treatment options," Dr. Elena Salagean, a consultant allergist at Holistic Allergy who was not involved in the present study, told Newsweek.
Promisingly, in a mouse model of the potentially life-threatening and rapid allergic reaction, anaphylaxis, knocking out USP5 or treatment with the USP5 inhibitor called WP1130 was found to prevent mast cells from releasing the molecules and weakened allergic reactions.
"The study shows a new potential target in reducing the release of histamine following contact with an allergen. Reducing histamine release from mast cells by blocking enzyme USP5 that's inside the mast cells means that less histamine will be released, so allergic reactions might be much milder," Dr. Salagean observed.
"Previous studies have tried to block the whole of the mast cell receptors, with varying success. Rather than trying that, the novel part in this study is that it's targeting the receptor machinery, an enzyme called USP5 inside the cells, and by doing so, it affects how well this receptor works."
Patient injecting let with auto epinephrine injector.
Patient injecting let with auto epinephrine injector.
Getty Images/AndreyPopov
The research team also revealed that the interaction between IgE and FcεRI binding caused USP5 to perform a process called deubiquitylation, removing molecules from proteins.
The biochemical modification further increased the stability of FcεRI, making the allergic reaction worse in terms of both strength and the time it lasts.
"Current treatments work through various different ways, mostly blocking the downstream effects of mast cell activation. Antihistamines and steroids also block certain mediators, while biologics block chemicals and other enzymes in the allergy pathway," explained Dr. Salagean.
"A USP5 inhibitor would be a direct blocker that works upstream at the control system of the mast cell receptors. By blocking this, it could reduce several mediators at the same time and reduce the strength of the mast cells response to an allergic reaction."
Anaphylaxis is currently primarily treated with epinephrine (adrenaline), which can be administered with an auto-injector like an EpiPen, as well as urgent medical care.
"It's all still early animal study findings but if one can design a drug that specifically targets and inhibits the USP5 enzyme, then it might have real potential. The difficulty lies in delivering it to right cells and making it selective enough, so it doesn't affect other enzymes or pathways at the same time. It's a long way out from being relevant to patients yet," added Dr. Salagean.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about allergy treatments? Let us know via health@newsweek.com.
Reference
Zhou, Z.-W., Xu, X.-T., Liang, Q.-N., Zhou, Y.-M., Hu, W.-Z., Liu, S., Jiao, Y.-X., Zhang, S.-C., Ji, K., & Chen, J.-J. (2025). USP5 deubiquitylates and stabilizes FcεRIγ to enhance IgE-induced mast cell activation and allergic inflammation. Science Signaling, 18(799). https://doi.org/10.1126/scisignal.adr3411
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
7 hours ago
- Newsweek
Freeze Dried Fruit Recall Sparks Warning to Customers Across the US
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Doehler Dry Ingredient Solutions, LLC is recalling the Member's Mark brand of freeze-dried fruit variety packs due to fears the product is contaminated with Listeria monocytogenes. Newsweek attempted to reach the company via phone on Friday for comment but could not leave a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. Listeria monocytogenes is a bacterium that poses significant health risks, particularly to pregnant women, newborns, older adults, and individuals with weakened immune systems, according to the FDA. What To Know In the alert, the FDA notes that the products were distributed from July 1, 2025, until July 25, 2025, at Sam's Club retail locations. The states and territories impacted by this recall are: Alabama Arizona California Colorado Connecticut Delaware Florida Georgia Hawaii Iowa Indiana Illinois Idaho Kansas Louisiana Maryland Maine Mississippi Minnesota Missouri Michigan Montana North Carolina North Dakota Nebraska New Hampshire New Jersey New Mexico Nevada New York Ohio Oklahoma Pennsylvania South Carolina South Dakota Tennessee Texas Utah Virginia Wisconsin West Virginia Wyoming Puerto Rico The Member's Mark Freeze Dried Fruit Variety Pack's being recalled are in 15 count boxes with a UPC number of 1 93968 50900 2, the FDA said. The agency added that no illnesses have been reported as of Thursday. The alert has a chart listing the recalled products with corresponding lot code numbers and use by dates for consumers to cross reference. The problem was discovered via "internal testing," the FDA says. A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) What People Are Saying The FDA on its website in part about the incubation period for Listeria infection: "There can be a substantial delay between the time of ingestion of contaminated food and the onset of serious symptoms. The average time from exposure to illness is approximately 30 days, but symptoms can appear as long as 90 days after exposure. It is important for consumers to know that the infection can occur as much as 90 days later, so that they can seek appropriate treatment if they have symptoms of Listeria infection." What Happens Next? Consumers are advised to contact Doehler Dry Ingredient Solutions, LLC's Customer Service via phone at (770) 387-0451 on weekdays from 8 a.m. to 5 p.m. ET with any additional questions, the FDA says. Health authorities continue to emphasize the importance of proper food storage and handling, particularly for ready-to-eat items. The FDA advises consumers to refrigerate perishable foods at and under 40°F, discard recalled products and properly sanitize surfaces that may have contacted suspected contaminated items to prevent the risk of cross-contamination.
Newsweek
7 hours ago
- Newsweek
Half of Baby Boomers Spend More Than Three Hours on Their Phones Daily
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Half of baby boomers are spending more than three hours on their phones each day, according to a new survey from The older age cohort, which includes ages 61 to 79, showed signs of potential digital addiction despite stereotypes that phone and social media overuse mainly impacts younger age groups. Why It Matters The report from found that 50 percent of their mostly baby boomer sample reported spending more than three hours daily on their smartphones. Roughly 20 percent spent more than five hours per day. Adults are recommended to limit their recreational screen time to less than two hours per day, according to A report from found that 50 percent of their mostly baby boomer sample reported spending more than three hours daily on their smartphones. A report from found that 50 percent of their mostly baby boomer sample reported spending more than three hours daily on their To Know A 2024 study from Pew Research discovered that nearly half of American teens are online "almost constantly," but that behavior isn't limited to young Americans. While baby boomers grew up without cellphones and the internet, they have a high usage rate of cellular devices in their golden years. The survey was based on responses from 2,000 people ages 59 to 77, making the majority of respondents baby boomers. Of that group, 40 percent said they felt anxious or uncomfortable when they don't have access to their digital devices. And 50 percent said they check their phone within an hour of waking up every day. What People Are Saying HR consultant and generational expert Bryan Driscoll told Newsweek: "Boomers spend hours glued to their phones, but it's not connection—it's isolation. Many struggle to separate fact from fiction online, making them more vulnerable to misinformation and digital echo chambers. This isn't just about screen time, it's about a generation grappling with loneliness and a shifting sense of what's real." Ruth Hernandez, a mental health counselor at told Newsweek: "Honestly, it's not that surprising anymore to see baby boomers spending hours on their phones. Many of them use smartphones for everything these days, such as texting with family, managing their health apps, reading the news, staying in touch on social media, and even streaming shows or watching videos. It's become part of their daily routine, just like it is for younger folks." What Happens Next The findings of the survey indicate that digital addiction is not a problem exclusive to younger generations, Hernandez said. "This really pushes back on the old stereotype that older people aren't tech-savvy or don't care about digital life," she said. "The truth is, boomers have adapted, many of them pretty quickly, and in some cases, they're just as glued to their screens as the rest of us. "At the end of the day, it shows that digital habits aren't tied to age anymore. They've become part of how we all live, work and connect. Whether you're 25 or 75, the pull of your phone is real."
Newsweek
8 hours ago
- Newsweek
Medicare Update: Trump Admin Launching Pilot Program to Cover Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Trump administration is preparing a five-year pilot program that would allow Medicare and Medicaid to cover some of the most in-demand weight-loss drugs, a move that could transform obesity treatment for millions of Americans. The plan, which includes medications such as Ozempic, Wegovy, Mounjaro and Zepbound, represents a reversal in federal policy and signals a broader willingness to use public insurance to address the nation's obesity epidemic. Why It Matters The drugs, known as GLP-1 receptor agonists, were initially developed to treat Type 2 diabetes but have become a cultural phenomenon for their ability to suppress appetite and help patients lose as much as 20 percent of their body weight in clinical trials. The pilot builds on a proposal introduced in the final months of the Biden administration but shelved earlier this year when officials under President Donald Trump announced Medicare and Medicaid would not cover weight-loss medications. What To Know According to documents obtained by The Washington Post, the program would allow state Medicaid programs and Medicare Part D plans to voluntarily cover GLP-1 drugs for weight management. The initiative is scheduled to begin in April 2026 for Medicaid and January 2027 for Medicare and will be administered through the Center for Medicare and Medicaid Innovation, which tests new payment models designed to reduce costs and improve care. Chiquita Brooks-LaSure, who led the Centers for Medicare and Medicaid Services under former President Joe Biden, told the Post the experiment would be a "game changer" if it expands access to obesity treatments. "Increased coverage of anti-obesity medications in Medicare and Medicaid was a priority during my tenure because scientists and clinicians increasingly believe obesity is a serious health condition that should be treated accordingly," she said. A pharmacy owner displays an Ozempic package in Pristina, Kosovo, on March 27. A pharmacy owner displays an Ozempic package in Pristina, Kosovo, on March 27. Photo by ARMEND NIMANI/AFP via Getty Images The program faces a major hurdle: price. GLP-1 drugs typically cost from $5,000 to $7,000 a year, raising questions about whether widespread coverage is sustainable. "The short-term cost is still huge," Dr. Cynthia Cox, vice president at KFF (formerly Kaiser Family Foundation), told Newsweek. "$1,000 a month per person is a massive outlay." A KFF analysis found that Ozempic's U.S. list price is $936 a month—more than five times the cost in Japan, where it sells for $169. Wegovy, which contains the same active ingredient, costs roughly $1,349 a month in the U.S., compared to $328 in Germany. At the moment, 13 state Medicaid programs cover GLP-1 drugs for obesity. Medicare limits coverage to patients with related conditions such as diabetes or heart disease. With about 70 million people enrolled in Medicaid and 65 million in Medicare, even partial expansion could affect a significant share of the population. Ethicists warn of the potential economic fallout. "These drugs help over 50 percent of people lose up to 25 percent of their body weight," said Dr. Robert Klitzman, a Columbia University bioethicist, in an interview with Newsweek. "But they cost around $12,000 a year. If two-thirds of Americans needed them, it would bankrupt the health care system." Despite the financial concerns, GLP-1 medications are generating enthusiasm among doctors for their ability to improve multiple health markers beyond weight loss. Clinical trials show they can reduce blood sugar, lower blood pressure and improve cardiovascular outcomes. "Ozempic and other GLP-1 drugs are changing how we approach obesity, both in the doctor's office and for society in general," Dr. Raj Dasgupta, chief medical adviser for Garage Gym Reviews, told Newsweek. "They're helping shift the conversation from 'this is a personal failure' to 'this is a medical condition that deserves real treatment.'" The Congressional Budget Office estimates that adding obesity coverage could cost Medicare $35 billion from 2026 to 2034. What People Are Saying A spokesperson for Novo Nordisk, which manufactures Ozempic and Wegovy, told The Washington Post: "We believe that comprehensive coverage through government and commercial insurance plans is critical to affordable health care and treatment options." Klitzman also said in the interview with Newsweek: "Insurance doesn't always cover it, especially for people who don't have diabetes or heart disease. Initially, the drugs were approved for diabetes-related obesity, but doctors have been prescribing them to people who are just overweight, without those conditions." What Happens Next With more than 100 million U.S. adults classified as obese and 22 million considered severely obese, according to the Centers for Disease Control and Prevention, the program's potential impact is vast. The proposal is not final and could undergo a formal public comment period before implementation.
